Skip to main content

Table 3 Sensitivity and specificity of each marker for determination of CIMP-high

From: Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer

Marker Total no. CIMP-1 (≥4/5) CIMP-2 (≥3/5) CIMP-3 (≥5/8)
Positive (sensitivity)a Negative (specificity)b Positive (sensitivity) a Negative (specificity) b Positive (sensitivity) a Negative (specificity) b
  401 34 (8.5%) 367 48 (12%) 353 41 (10.2%) 360
CACNA1G
 (+) 80 (20%) 33 (97%) 47 38 (79%) 42 34 (83%) 46
 (−) 321 1 320 (87%) 10 311 (88%) 7 314 (87%)
CDKN2A
 (+) 231 (57.6%) 33 (97%) 198 38 (79%) 193 37 (90%) 194
 (−) 170 1 169 (46%) 10 160 (45%) 4 166 (46%)
CRABP1
 (+) 199 (49.6%) 34 (100%) 165 45 (94%) 154 40 (98%) 159
 (−) 202 0 202 (55%) 3 199 (56%) 1 201 (56%)
IGF2
 (+) 123 (30.7%) 24 (71%) 99 40 (83%) 83 34 (83%) 89
 (−) 278 10 268 (73%) 8 270 (77%) 7 271 (75%)
MLH1
 (+) 15 (3.7%) 5 (15%) 10 4 (8.3%) 11 4 (9.8%) 11
 (−) 386 29 357 (97%) 44 342 (97%) 37 349 (97%)
NEUROG1
 (+) 125 (31.2%) 33 (97%) 92 43 (90%) 82 39 (95%) 86
 (−) 276 1 275 (74%) 5 271 (77%) 2 274 (76%)
RUNX3
 (+) 29 (7.2%) 16 (47%) 13 27 (56%) 2 25 (61%) 4
 (−) 372 18 354 (96%) 21 351 (99%) 16 356 (99%)
SOCS1
 (+) 68 (17%) 13 (38%) 55 24 (50%) 44 19 (46%) 49
 (−) 333 21 312 (85%) 24 309 (88%) 22 311 (86%)
  1. aSensitivity of each marker is defined as the number of CIMP-high cases positive for a given marker divided by the number of all CIMP-high cases
  2. bSpecificity of each marker is defined as the number of non-CIMP-high cases negative for a given marker divided by the number of all non-CIMP-high cases